Abstract
The effect of infusing DDAVP and cryoprecipitate either singly or in combination was studied in a patient with variant von Willebrand disease. Both DDAVP and cryoprecipitate caused only partial correction in the hemostatic defect when used as a single agent. A combination of DDAVP and cryoprecipitate induced a complete correction of the hemostatic defect as well as factor VIII related properties.
Publication types
-
Case Reports
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Deamino Arginine Vasopressin / administration & dosage
-
Deamino Arginine Vasopressin / therapeutic use
-
Drug Therapy, Combination
-
Factor VIII / administration & dosage
-
Factor VIII / therapeutic use*
-
Fibrinogen / administration & dosage
-
Fibrinogen / therapeutic use*
-
Genetic Variation
-
Humans
-
Infusions, Parenteral
-
Male
-
Middle Aged
-
von Willebrand Diseases / drug therapy
-
von Willebrand Diseases / genetics*
Substances
-
cryoprecipitate coagulum
-
Factor VIII
-
Fibrinogen
-
Deamino Arginine Vasopressin